China Health : Supplementary announcement of COVID-19 risk of death reduced by 89%, R

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CHINA HEALTH GROUP INC.

中 國 醫 療 集 團 有 限 公 司

(Carrying on business in Hong Kong as "萬全醫療集團") (Incorporated in the Cayman Islands with limited liability)

(Stock Code: 08225)

Supplementary announcement of

COVID-19 risk of death reduced by 89%, Ritonavir associated with the Group was found to work miraculously with Pfizer's new drug

On November 7, 2021, China Health Group (the " Group ") issued the voluntary announcement "COVID-19 risk of death reduced by 89%, the combination of ritonavir studied by China Health Group and Pfizer's new drug creates a miracle" is supplemented as follows:

How will the Group benefit from product sales in the long term?

Maikexin is the only approved domestic ritonavir oral liquid in Chinese mainland. The Group participated in the study. The Group related enterprises Venturepharm were awarded the approval. The approval number of raw materials was H20040411, and the approval number of the preparation was H20051019. The Group's revenue is usually research service CRO and scientific research business promotion service CRSO. Therefore, the Group will benefit from product sales for a long time.

Why can ritonavir combined with Pfizer create miracles in reducing the risk of death of COVID-19?

The center of antiviral drugs clinical research of the Group and the world's top research institutes have found that a group of anti AIDS drugs can play an active role in the fight against SARS virus. Ritonavir is an aspartic protease inhibitor of human immunodeficiency virus-1(HIV-1) and human immunodeficiency virus-2(HIV-2).COVID-19 and HIV virus belong to coronavirus. Ritonavir may play a role through the same mechanism.

It is reported that in this combined use, the combination of low-dose ritonavir and PF- 07321332 can slow down the metabolism / decomposition of PF-07321332 in vivo, so as to maintain a high concentration in vivo to fight the virus.

In the epidemic and post epidemic era, the Group will benefit from big data of related diseases and clinical research of drugs for a long time

The Group's "RWS virus clinical research center" plans to re screen and group existing drugs through big data real-world clinical research to find the best treatment. Since the beginning of SARS in 2008, the Group has set up a special action group for digital clinical research, led by Dr. Song Xuemei, who is engaged in clinical research on the fight against SARS, and has worked with Peking University, Concordia Medical College and Tongji University in Wuhan to carry out screening of antiviral drugs. In 2020, when COVID-19 broke out, ritonavir and other pharmaceutical research were carried out. In addition to the discovery of a number of drugs such as ritonavir on New Coronavirus (2019-nCoV), but also including Yue ting and other drugs to reduce the 2019-nCoV death of smokers, as well as the prevention and treatment of depression and allergic reactions brought by the 2019-nCoV. The epidemic will coexist with mankind for a long time, and the Group will continue to benefit from this health defense war.

China Health Group Inc. is a leading enterprise that, driven by the three cores of the Real World Study, Real World Data and Artificial Intelligence, provides three major services for life sciences, precision digital medical "research-based specialty" CHGmyD services, Real World Study CHGRWS services and the Scientific research product promotion service of reconstructing the trillion dollar drug promotion market CRSO services. The Group focuses on the three century epidemic diseases of brain science, allergy and antiviral, and constructs five specialty brands: baimin Kangmin, Xixin spirit, Xien prevention and treatment of stroke mania, Yuejie smoking addiction , Special viral drugs and rare disease.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company and, in case of doubt, to seek independent advice from professionals or financial advisers.

By order of the Board

China Health Group Inc.

GUO Xia

Chairman

Hong Kong, 9 November 2021

As at the date hereof, the Board comprises two executive Directors, being Mr. GUO Xia and Dr. SONG Xuemei; one non- executive Director, being Mr. SU Yi; and three independent non-executive Directors, being Mr. QIU Rui, Dr. NI Binhui and Mr. ZHEN Ling.This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading. This announcement will remain on the "Latest Listed Company Information" page of the GEM website at http://www.hkgem.com for 7 days from the date of its posting. This announcement will also be posted on the Company's website at http://www.chgi.net.